BEAM THERAPEUTICS INC (BEAM)

First Week of June 21st Options Trading For Beam Therapeutics (BEAM)

BEAM Makes Notable Cross Below Critical Moving Average

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)...

Beam stock slips after mixed shelf offering (NASDAQ:BEAM)

After a sharp rally in the previous session. Beam Therapeutics (BEAM) stock trades lower as the company files for a mixed-shelf securities offering. Read more here.

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines...

Notable Tuesday Option Activity: OZK, AMBA, BEAM

BMO starts Korro at outperform, cites upcoming data for AATD drug (NASDAQ:KRRO)

BMO initiated coverage of Korro Bio (KRRO) with an outperform rating, citing upcoming data for its AATD drug candidate KRRO-110 and potential partnerships. Read more here.

Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug

Both companies are working on treatments for genetic disorders.

Beam stock jumps as Eli Lilly deal brings Q4 beat (NASDAQ:BEAM)

Beam Therapeutics (BEAM) stock gains as the company reports profits in Q4 after boosting revenue thanks to a collaboration deal with Eli Lilly (LLY). Read more here.

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024

Beam Therapeutics Stock Shows Healthy Relative Strength Improvement

In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.

3 Biotech Stocks to Buy on the Dip: February 2024

Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines...

Why Beam Therapeutics Stock Zoomed 17% Higher Today

JPMorgan Chase becomes the latest institution in the company's bull pen.

JP Morgan upgrades Beam to overweight, cites AATD therapy potential (NASDAQ:BEAM)

JP Morgan upgraded Beam Therapeutics (BEAM) to overweight, citing the potential of its AATD treatment candidate BEAM-302.

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Analysts have high hopes for these three innovation companies in 2024.

3 Stocks to Buy in the Booming Field of Gene Editing

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.